The characteristics of juvenile myasthenia gravis among South Africans

South African Medical Journal

Volumn 102, Issue 6, 2012, Pages 532-536

  Heckmann, J M ^a   Hansen, P ^b   van Toorn, R ^c   Lubbe, E ^d   Janse van Rensburg, E ^e   Wilmshurst, J ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF PRETORIA   (South Africa)

^e UNIVERSITY OF THE FREE STATE   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN; PREDNISONE; PYRIDOSTIGMINE; STEROID; ANTIBODY; CHOLINERGIC RECEPTOR; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CHILD; DEATH; DISEASE SEVERITY; FATIGUE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; OPHTHALMOPLEGIA; PLASMAPHERESIS; PRESCHOOL CHILD; PTOSIS; REMISSION; SCHOOL CHILD; SOUTH AFRICA; THYMECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE; WEAKNESS; ANALYSIS OF VARIANCE; BLOOD; EYE DISEASE; IMMUNOLOGY; NONPARAMETRIC TEST; ONSET AGE;

ADOLESCENT; ADULT; AGE OF ONSET; ANALYSIS OF VARIANCE; ANTIBODIES; CHILD; CHILD, PRESCHOOL; EYE DISEASES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MYASTHENIA GRAVIS; PLASMA EXCHANGE; PREDNISONE; RECEPTORS, CHOLINERGIC; REMISSION INDUCTION; SOUTH AFRICA; STATISTICS, NONPARAMETRIC; THYMECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865107371     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.5390     Document Type: Article

References (12)

1. Bateman KJ, Schinkel M, Little F, Liebenberg L, Vincent A, Heckmann JM. Incidence of seropositive myasthenia gravis in Cape Town and South Africa. S Afr Med J 2007;97(10):959-962.
2. Rodriguez M, Gomez MR, Howard FM, Jr., Taylor WF. Myasthenia gravis in children: long-term follow-up. Ann Neurol 1983;13(5):504-510.
3. Evoli A. Acquired myasthenia gravis in childhood. Curr Opin Neurol 2010;23(5):536-540.
4. Heckmann JM, Owen EP, Little F. Myasthenia gravis in South Africans: racial differences in clinical manifestations. Neuromuscul Disord 2007;17(11-12):929-934.
5. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55(1):16-23.
6. Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve 2009;39(4):423-431.
7. Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology 2000;107(3):504-510.
8. Kim JH, Hwang JM, Hwang YS, Kim KJ, Chae J. Childhood ocular myasthenia gravis. Ophthalmology 2003;110(7):1458-1462.
9. Heckmann JM, Uwimpuhwe H, Ballo R, Kaur M, Bajic VB, Prince S. A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis. Genes Immun 2010;11:1-10. [http://dx.doi.org/10.1038/gene.2009.61]
10. Andrews PI, Massey JM, Howard JF jun., Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 1994;44(7):1208-1214.
11. Aban IB, Wolfe GI, Cutter GR, et al. The MGTX experience: challenges in planning and executing an international, multicenter clinical trial. J Neuroimmunol 2008;201-202:80-84.
12. Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011;11:97. [http://dx.doi.org/10.1186/1471-2377-11-97]